Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.51 |
| ▸ | PPARA | Q07869 | 8/20 | 0.51 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850689 | 0.81 | PSEN1 (0.44) | PPARDPPARAPPARGMAPT | |
| SCHEMBL4466730 | 0.76 | PPARD (0.51) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL4468965 | 0.76 | PPARD (0.53) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL6224733 | 0.76 | PPARD (0.52) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL6221957 | 0.74 | PPARD (0.49) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL6221959 | 0.74 | PPARD (0.51) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL5852351 | 0.73 | CYP2C9 (0.41) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL4480854 | 0.72 | PPARD (0.62) | PPARDPPARAPPARG | |
| SCHEMBL5057764 | 0.71 | PSEN1 (0.46) | PPARDPPARAPPARGMAPTTP53 | |
| SCHEMBL4476635 | 0.70 | PPARD (0.49) | PPARDPPARAPPARGMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | claimed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | claimed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.